Shawn Peavie, DO
Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1578899951
Payments from drug & device makers
Across 539 payments — averaging $373.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$58K
- Novo Nordisk$46K
- Dexcom, Inc.$44K
- Xeris Pharmaceuticals, Inc.$36K
- Sanofi-aventis U.S. LLC$15K
- Insulet Corporation$287
- plus $2K from 24 others
What the payments were for
- Consulting fees$12,7656%
- Speaking & faculty fees$167,43183%
- Travel & lodging$7,9414%
- Food & beverage$12,9366%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 92 | $57,761 |
| Novo Nordisk | 111 | $46,046 |
| Dexcom, Inc. | 168 | $44,427 |
| Xeris Pharmaceuticals, Inc. | 56 | $36,234 |
| Sanofi-aventis U.S. LLC | 19 | $14,573 |
| Insulet Corporation | 22 | $287 |
| Corcept Therapeutics | 13 | $249 |
| Abbott | 10 | $194 |
| Boston Scientific | 2 | $182 |
| Sequel Med Tech, LLC | 2 | $146 |
| BETA Bionics, Inc. | 1 | $139 |
| Tandem Diabetes Care, Inc. | 5 | $130 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| Novartis | 4 | $82 |
| Radius Health, Inc. | 4 | $65 |
| Mannkind Corporation | 4 | $64 |
| Embecta Corp. | 2 | $58 |
| Lilly USA, LLC | 4 | $54 |
| Amryt Pharma Holdings Ltd | 2 | $53 |
| AbbVie | 3 | $52 |
| Bayer | 1 | $39 |
| Boehringer Ingelheim | 2 | $29 |
| Antares Pharma, Inc. | 2 | $28 |
| Roche Diabetes Care, Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $25 |
| Lifescan, Inc. | 2 | $24 |
| Merck | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $14 |
| Vivus LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$56,147
- DEXCOM G7 GSS (161)$41,449
- GVOKE HYPOPEN$34,978
- RYBELSUS$22,280
- Ozempic$22,149
- TZIELD$14,312
- DEXCOM STELO GLUCOSE BIOSENSOR$8,517
- iLet Bionic Pancreas$417
- DEXCOM G6 TRANSMITTER$247
- WaveWriter Alpha Prime 16$145
- TWIIST$138
- Auvelity$124
How this compares
$201,155 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 315 | $464,230 |
| TrulicityDulaglutide | 170 | $206,989 |
| FarxigaDapagliflozin Propanediol | 178 | $194,985 |
| JardianceEmpagliflozin | 92 | $115,006 |
| MounjaroTirzepatide | 100 | $108,974 |
| JanuviaSitagliptin Phosphate | 95 | $105,902 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $77,154 |
| Tresiba Flextouch U-100Insulin Degludec | 90 | $76,295 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $60,359 |
| Novolog FlexpenInsulin Aspart | 91 | $33,265 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $25,657 |
| OmnitropeSomatropin | 16 | $20,054 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 134 | $19,783 |
| Bydureon BciseExenatide Microspheres | 13 | $18,506 |
| RybelsusSemaglutide | 11 | $16,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $46,046 | $486,332352 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $54 | $321,420281 claims |
| AstraZenecaFarxiga | $57,761 | $194,985178 claims |
| Boehringer IngelheimJardiance, Tradjenta | $29 | $130,029103 claims |
| MerckJanuvia | $22 | $105,90295 claims |
| AbbVieSynthroid | $52 | $10,406111 claims |
| Antares Pharma, Inc.Xyosted | $28 | $8,98615 claims |
| Sanofi-aventis U.S. LLCLantus | $14,573 | $1,80012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Cincinnati
- Nelson WattsCincinnati$348K
- Amanda DenneyCincinnati$183K
- Robert CohenCincinnati$136K
- Shailendra PatelCincinnati$68K
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
- Bartolome BurgueraCleveland$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.